Not available
Quote | Cue Biopharma Inc. (NASDAQ:CUE)
Last: | $1.33 |
---|---|
Change Percent: | -5.67% |
Open: | $1.4 |
Close: | $1.41 |
High: | $1.44 |
Low: | $1.315 |
Volume: | 102,047 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Cue Biopharma Inc. (NASDAQ:CUE)
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at...
2024-04-09 12:15:02 ET Oppenheimer analyst issues UNDERPERFORM recommendation for CUE on April 9, 2024 10:01AM ET. The previous analyst recommendation was Underperform. CUE was trading at $1.9 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Message Board Posts | Cue Biopharma Inc. (NASDAQ:CUE)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $CUBT 29% v576K c.0271 f537,8M H.0275 ML.0101 | znewcar1 | investorshangout | 10/04/2022 11:55:20 PM |
CUE Insider Buy | conix | investorshub | 04/06/2022 1:32:33 AM |
News, Short Squeeze, Breakout and More Instantly...
Cue Biopharma Inc. Company Name:
CUE Stock Symbol:
NASDAQ Market:
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel clas...
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at...
2024-04-09 12:15:02 ET Oppenheimer analyst issues UNDERPERFORM recommendation for CUE on April 9, 2024 10:01AM ET. The previous analyst recommendation was Underperform. CUE was trading at $1.9 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...